AKT1 and pulmonary fibrosis: Accordingly, lung fibroblasts derived from patients affected by pulmonary fibrosis and treated with PI3K inhibitors show a reduction in the PI3K pathway measured through Akt phosphorylation and a consequent proliferation rate decrease in vitro [40].